Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'An Interventional Phase 3, Open Label, Randomized Study To Evaluate Efficacy And Safety of PF-08634404 in Combination With Chemotherapy Versus Pembrolizumab in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent Mismatch Repair (MMR) Proficient Endometrial Cancer'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National Cancer Centre
National University Hospital
Trial Status: NA
Principal Investigator(s):
Dr Chan Junjie Jack
Dr David Tan Shao Peng
Published by HT Digital Content Services with permission from Hea...